'Best Technology 2009' Award

RNS Number : 9985A
Immupharma PLC
19 October 2009
 





FOR IMMEDIATE RELEASE

19 OCTOBER 2009


 

ImmuPharma PLC


("ImmuPharma")


ImmuPharma wins 'Best Technology 2009' Award at the AIM Awards


ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has won the Best Technology Award at the AIM Awards 2009organized by the London Stock Exchange


The Award, announced at the AIM Awards Dinner in London on 15 October 2009is presented to the company which reflects the innovation and entrepreneurial skills that are considered the cornerstone of the AIM culture.


Commenting on the award, Richard Warr, Chairman of ImmuPharma said: "ImmuPharma is honoured to receive thBest Technology Award at the 2009 AIM Awards DinnerIt is a prestigious award and I should like to thank the AIM community for recognising the innovation and entrepreneurial skills that have driven ImmuPharma forward over the last few years. This Award builds on our success at the European MedisciencAwards in June 2009 where ImmuPharma was awarded the Breakthrough of the Year Award. For ImmuPharma the journey is very much beginning and to have received such public recognition over the past year is particularly rewarding."


- Ends -


For further information please contact: 


ImmuPharma PLC

+44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer 

Richard Warr, Chairman




Buchanan Communications

+44 20 7466 5000

Lisa Baderoon 




Panmure Gordon & Co                     

Andrew Burnett

Rakesh Sharma

+44 151 243 0963



Noble & Company Limited

+44 20 7763 2200

James Bromhead

Sam Reynolds




Notes to Editors


About ImmuPharma PLC


ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in MulhouseFrance and BasleSwitzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. 


Its lead candidate for the treatment of Lupus, LupuzorTMa chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009

The company also has a strong proprietary and collaborative drug development pipeline.





This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAMLBLTMMTBMPL

Companies

Immupharma (IMM)
UK 100

Latest directors dealings